• Paul L Hess, Sana M Al-Khatib, Joo Y Han, Rex Edwards, Gust H Bardy, J Thomas Bigger, Alfred Buxton, Riccardo Cappato, Paul Dorian, Al Hallstrom, Alan H Kadish, Peter J Kudenchuk, Kerry L Lee, Daniel B Mark, Arthur J Moss, Richard Steinman, Lurdes Y T Inoue, and Gillian Sanders.
• From the Duke Clinical Research Institute, Durham, NC (P.L.H., S.M.A., R.E., K.L.L., D.B.M., G.S.); University of Washington, Seattle (J.Y.H., G.H.B., A.H., P.J.K., L.Y.T.I.); Columbia University, New York, NY (J.T.B., R.S.); Beth Israel Deaconess Medical Center, Boston, MA (A.B.); I.R.C.C.S. Policlinico San Donato, Milan, Italy (R.C.); University of Toronto, Ontario, Canada (P.D.); Northwestern Feinberg School of Medicine, Chicago, IL (A.H.K.); and University of Rochester, Rochester, NY (A.J.M.). p.hess@duke.edu.
• Circ Cardiovasc Qual. 2015 Mar 1;8(2):179-86.

BackgroundThe impact of patient age on the risks of death or rehospitalization after primary prevention implantable cardioverter-defibrillator (ICD) placement is uncertain.Methods And ResultsData from 5 major ICD trials were merged: the Multicenter Automatic Defibrillator Implantation Trial I (MADIT-I), the Multicenter UnSustained Tachycardia Trial (MUSTT), the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II), the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Trial (DEFINITE), and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Median age at enrollment was 62 (interquartile range 53-70) years. Compared with their younger counterparts, older patients had a greater burden of comorbid illness. In unadjusted exploratory analyses, ICD recipients were less likely to die than nonrecipients in all age groups: among patients aged <55 years: hazard ratio 0.48, 95% posterior credible interval 0.33 to 0.69; among patients aged 55 to 64 years: hazard ratio 0.69, 95% posterior credible interval 0.53 to 0.90; among patients aged 65 to 74 years: hazard ratio 0.67, 95% posterior credible interval, 0.53 to 0.85; and among patients aged ≥75 years: hazard ratio 0.54, 95% posterior credible interval 0.37 to 0.78. Sample sizes were limited among patients aged ≥75 years. In adjusted Bayesian-Weibull modeling, point estimates indicate ICD efficacy persists but is attenuated with increasing age. There was evidence of an interaction between age and ICD treatment on survival (two-sided posterior tail probability of no interaction <0.01). Using an adjusted Bayesian logistic regression model, there was no evidence of an interaction between age and ICD treatment on rehospitalization (two-sided posterior tail probability of no interaction 0.44).ConclusionsIn this analysis, the survival benefit of the ICD exists but is attenuated with increasing age. The latter finding may be because of the higher burden of comorbid illness, competing causes of death, or limited sample size of older patients. There was no evidence that age modifies the association between ICD treatment and rehospitalization.© 2015 American Heart Association, Inc.

3 keywords...

hide…